|
1
|
Wada Y, Takami Y, Tateishi M, Ryu T,
Mikagi K and Saitsu H: Impact of more detailed categorization of
shrinkage or progression ratio at initial imaging response after
sorafenib treatment in advanced hepatocellular carcinoma patients.
OncoTargets Ther. 8:3193–3202. 2015. View Article : Google Scholar
|
|
2
|
Zender L, Villanueva A, Tovar V, Sia D,
Chiang DY and Llovet JM: Cancer gene discovery in hepatocellular
carcinoma. J Hepatol. 52:921–929. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bhangoo MS, Karnani DR, Hein PN, Giap H,
Knowles H, Issa C, Steuterman S, Pockros P and Frenette C:
Radioembolization with Yttrium-90 microspheres for patients with
unresectable hepatocellular carcinoma. J Gastrointest Oncol.
6:469–478. 2015.PubMed/NCBI
|
|
4
|
Song MJ and Bae SH: Newer treatments for
advanced hepatocellular carcinoma. Korean J Intern Med (Korean
Assoc Intern Med). 29:149–155. 2014.
|
|
5
|
Follit CA, Brewer FK, Wise JG and Vogel
PD: In silico identified targeted inhibitors of P-glycoprotein
overcome multidrug resistance in human cancer cells in culture.
Pharmacol Res Perspect. 3:e001702015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
McCormick JW, Vogel PD and Wise JG:
Multiple drug transport pathways through human P-glycoprotein.
Biochemistry. 54:4374–4390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Janigro D, Perju C, Fazio V, Hallene K,
Dini G, Agarwal MK and Cucullo L: Alternating current electrical
stimulation enhanced chemotherapy: A novel strategy to bypass
multidrug resistance in tumor cells. BMC Cancer. 6:722006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vesuna F, Bergman Y and Raman V: Genomic
pathways modulated by Twist in breast cancer. BMC Cancer.
17:522017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang H, Massi D, Hemmings BA, Mandalà M,
Hu Z, Wicki A and Xue G: AKT-ions with a TWIST between EMT and MET.
Oncotarget. 7:62767–62777. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Gong J, Kong D and Liu HY:
Anti-proliferation effects of Twist gene silencing in gastric
cancer SGC7901 cells. World J Gastroenterol. 21:2926–2936. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nantajit D, Lin D and Li JJ: The network
of epithelial-mesen-chymal transition: Potential new targets for
tumor resistance. J Cancer Res Clin Oncol. 141:1697–1713. 2015.
View Article : Google Scholar
|
|
13
|
Jiang ZS, Sun YZ, Wang SM and Ruan JS:
Epithelial-mesenchymal transition: Potential regulator of ABC
transporters in tumor progression. J Cancer. 8:2319–2327. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Deng JJ, Zhang W, Xu XM, Zhang F, Tao WP,
Ye JJ and Ge W: Twist mediates an aggressive phenotype in human
colorectal cancer cells. Int J Oncol. 48:1117–1124. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu YR, Liang L, Zhao JM, Zhang Y, Zhang
M, Zhong WL, Zhang Q, Wei JJ, Li M, Yuan J, et al: Twist1 confers
multidrug resistance in colon cancer through upregulation of
ATP-binding cassette transporters. Oncotarget. 8:52901–52912.
2017.PubMed/NCBI
|
|
16
|
Lu S, Yu L, Mu Y, Ma J, Tian J, Xu W and
Wang H: Role and mechanism of Twist1 in modulating the
chemosensitivity of FaDu cells. Mol Med Rep. 10:53–60. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Wu C, Xiong W, Chen C, Li R and
Zhou G: Knockdown of p54nrb inhibits migration, invasion and TNF-α
release of human acute monocytic leukemia THP1 cells. Oncol Rep.
35:3742–3748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li R, Zhao Y, Chen J, Shao S and Zhang X:
Fisetin inhibits migration, invasion and epithelial-mesenchymal
transition of LMP1-positive nasopharyngeal carcinoma cells. Mol Med
Rep. 9:413–418. 2014. View Article : Google Scholar
|
|
20
|
de Jong E, Winkel P, Poelstra K and
Prakash J: Anticancer effects of 15d-prostaglandin-J2 in wild-type
and doxorubicin-resistant ovarian cancer cells: Novel actions on
SIRT1 and HDAC. PLoS One. 6:e251922011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhuo X, Chang A, Huang C, Yang L, Xiang Z
and Zhou Y: Expression of TWIST, an inducer of
epithelial-mesenchymal transition, in nasopharyngeal carcinoma and
its clinical significance. Int J Clin Exp Pathol. 7:8862–8868.
2014.
|
|
22
|
Zhang YQ, Wei XL, Liang YK, Chen WL, Zhang
F, Bai JW, Qiu SQ, Du CW, Huang WH and Zhang GJ: Over-expressed
Twist associates with markers of epithelial mesenchymal transition
and predicts poor prognosis in breast cancers via ERK and Akt
activation. PLoS One. 10:e01358512015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chun HW and Hong R: Significance of the
hedgehog pathway-associated proteins Gli-1 and Gli-2 and the
epithelial-mesenchymal transition-associated proteins Twist and
E-cadherin in hepatocellular carcinoma. Oncol Lett. 12:1753–1762.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang L, Hou Y, Yuan J, Tang S, Zhang H,
Zhu Q, Du YE, Zhou M, Wen S, Xu L, et al: Twist promotes
reprogramming of glucose metabolism in breast cancer cells through
PI3K/AKT and p53 signaling pathways. Oncotarget. 6:25755–25769.
2015.PubMed/NCBI
|
|
25
|
Zhou Y, Zhang H, Zhuo X, Liu Y, Zhang G
and Tan Y: Over-expression of TWIST, an epithelial-mesenchymal
transition inducer, predicts poor survival in patients with oral
carcinoma. Int J Clin Exp Med. 8:9239–9247. 2015.PubMed/NCBI
|
|
26
|
Zhu K, Chen L, Han X and Wang J and Wang
J: Short hairpin RNA targeting Twist1 suppresses cell proliferation
and improves chemosensitivity to cisplatin in HeLa human cervical
cancer cells. Oncol Rep. 27:1027–1034. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi XP, Miao S, Wu Y, Zhang W, Zhang XF,
Ma HZ, Xin HL, Feng J, Wen AD and Li Y: Resveratrol sensitizes
tamoxifen in antiestrogen-resistant breast cancer cells with
epithelial-mesenchymal transition features. Int J Mol Sci.
14:15655–15668. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song J and Li Y: miR-25-3p reverses
epithelial-mesenchymal transition via targeting Sema4C in
cisplatin-resistance cervical cancer cells. Cancer Sci. 108:23–31.
2017. View Article : Google Scholar
|
|
29
|
Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang
X, Wang Z, Yang Y, Chen C, Wang Z, et al: The
PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal
transition in gemcitabine resistance hepatoma cells. Oncotarget.
6:7000–7010. 2015.PubMed/NCBI
|
|
30
|
Ye CG, Yeung JH, Huang GL, Cui P, Wang J,
Zou Y, Zhang XN, He ZW and Cho CH: Increased glutathione and
mitogen-activated protein kinase phosphorylation are involved in
the induction of doxorubicin resistance in hepatocellular carcinoma
cells. Hepatol Res. 43:289–299. 2013. View Article : Google Scholar
|
|
31
|
Ye CG, Wu WK, Yeung JH, Li HT, Li ZJ, Wong
CC, Ren SX, Zhang L, Fung KP and Cho CH: Indomethacin and SC236
enhance the cytotoxicity of doxorubicin in human hepatocellular
carcinoma cells via inhibiting P-glycoprotein and MRP1 expression.
Cancer Lett. 304:90–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun J, Yeung CA, Co NN, Tsang TY, Yau E,
Luo K, Wu P, Wa JC, Fung KP, Kwok TT, et al: Clitocine reversal of
P-glycoprotein associated multi-drug resistance through
down-regulation of transcription factor NF-κB in R-HepG2 cell line.
PLoS One. 7:e407202012. View Article : Google Scholar
|
|
33
|
Jin S and Scotto KW: Transcriptional
regulation of the MDR1 gene by histone acetyltransferase and
deacetylase is mediated by NF-Y. Mol Cell Biol. 18:4377–4384. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang
J, Zhu J, Chen L, Bao X, Liu Y, et al: miR-495 sensitizes MDR
cancer cells to the combination of doxorubicin and taxol by
inhibiting MDR1 expression. J Cell Mol Med. 21:1929–1943. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feng R and Dong L: Knockdown of
microRNA-127 reverses adriamycin resistance via cell cycle arrest
and apoptosis sensitization in adriamycin-resistant human glioma
cells. Int J Clin Exp Pathol. 8:6107–6116. 2015.PubMed/NCBI
|
|
36
|
Ma H, Yue X, Gao L, Liang X, Yan W, Zhang
Z, Shan H, Zhang H, Spear BT and Ma C: ZHX2 enhances the
cytotoxicity of chemotherapeutic drugs in liver tumor cells by
repressing MDR1 via interfering with NF-YA. Oncotarget.
6:1049–1063. 2015. View Article : Google Scholar :
|
|
37
|
Saxena M, Stephens MA, Pathak H and
Rangarajan A: Transcription factors that mediate
epithelial-mesenchymal transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis. 2:e1792011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chao HM, Huang HX, Chang PH, Tseng KC,
Miyajima A and Chern E: Y-box binding protein-1 promotes
hepatocellular carcinoma-initiating cell progression and
tumorigenesis via Wnt/β-catenin pathway. Oncotarget. 8:2604–2616.
2017. View Article : Google Scholar
|
